Xilio Therapeutics vs Zymeworks
XLO and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How XLO and ZYME compare
Zymeworks is the larger company, worth 40 times as much as Xilio Therapeutics ($1.9B against $46.7M).
Zymeworks grew revenue faster over the last twelve months (97.8% versus 73.0% for Xilio Therapeutics).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with −20.9% at Xilio Therapeutics.
Xilio Therapeutics scores higher on the StockData Score (11 against 10 for Zymeworks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | XLO | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $46.7M | $1.9B |
| Share price | $8.07 | $26.24 |
| Change, 1 year | −25.4% | 35.5% |
| Change, 5 years | −97.5% | 32.5% |
| Beta (5Y) | 0.89 | 0.83 |
| Employees | 76 | 264 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 50.5× |
| P/S | 0.8× (better) | 7.0× |
| P/B | 0.7× (better) | 7.2× |
| EV/EBITDA | – | 39.9× |
| FCF yield | −123% | −6.1% (better) |
| Fair value | $31.67 | $12.07 |
| Margin of safety | 74.5% (better) | −117% |
| Growth | ||
| Revenue growth (TTM) | 73.0% | 97.8% (better) |
| Revenue growth, 5Y average | – | 22.2% |
| Profitability | ||
| Operating margin | −74.9% | 16.6% (better) |
| Net margin | −20.9% | 16.3% (better) |
| FCF margin | −105% | −42.4% (better) |
| Return on equity | −38.2% | 15.0% (better) |
| Return on invested capital | – | 21.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.72 (better) | 3.30 |
| Altman Z-score | −3.87 | 0.74 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 8.9% |
| Shareholder yield | 0.00% | 8.9% (better) |
| Ownership | ||
| Held by institutions | 58.9% | 98.1% |
| Held by insiders | – | 58.9% |
| Insider net buying, 12 months | $38.3K (better) | −$5.0M |
| Short interest, % of float | – | 20.3% |
Go deeper
- XLO stock overview
- XLO income statement
- XLO valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.